Podium Presentation
Where: Pharma CI USA 2026, Newark, NJ
When: Wednesday, September 16, 2026 | 1:00 PM ET
China has become a global leader in oncology and immunology innovation and a key player in the commercial market for multinational pharma, yet it remains a persistent CI blind spot.
Early clinical signals are often buried in China-based platforms and investigator-led trials. Secondary data can be difficult to access, while robust primary intelligence is challenging to gather due to language and cultural barriers. As a result, many organizations are reacting to developments rather than anticipating them, even when they already have operations in China.
At Pharma CI USA, our session explores why standard global CI frameworks fall short in China and what organizations need to do differently.
During this session we’ll discuss:
- Why standard global CI frameworks fall short in China
- How to uncover early signals from local and non-traditional sources
- The impact of evolving regulatory and access dynamics
- The intensifying race to license or acquire breakthrough assets
- How leading organizations are making China a central pillar of their CI strategy
This session sets out a practical framework to move China from a regional afterthought to a central pillar of global CI capability, actively driving insights and strategic decisions.
ABOUT THE EVENT
Pharma CI USA is the premier competitive intelligence gathering for senior pharmaceutical, biotechnology and medical device executives.
Meet the Prescient team throughout the conference to discuss how we help organizations:
- Monitor increasingly complex competitive landscapes
- Identify early signals before competitors
- Generate actionable competitive intelligence
- Support faster, more confident strategic decision-making
We’re looking forward to seeing you in Newark.